Lee Sul A, Riella Leonardo V
Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Center for Transplantation Sciences, Massachusetts General Hospital, Boston, Massachusetts, USA.
Kidney Int Rep. 2024 Mar 1;9(6):1601-1613. doi: 10.1016/j.ekir.2024.02.1435. eCollection 2024 Jun.
Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) have evolved from their initial role as antidiabetic drugs to garner recognition for their remarkable cardio-protective and reno-protective attributes. They have become a crucial component of therapeutic guidelines for congestive heart failure and proteinuric chronic kidney disease (CKD). These benefits extend beyond glycemic control, because improvements in cardiovascular and renal outcomes occur swiftly. Recent studies have unveiled the immunomodulatory properties of SGLT2 inhibitors; thus, shedding light on their potential to influence the immune system and inflammation. This comprehensive review explores the current state of knowledge regarding the impact of SGLT2 inhibitors on the immune system and inflammation, focusing on preclinical and clinical evidence. The review delves into their antiinflammatory and immunomodulating effects, offering insights into clinical implications, and exploring emerging research areas related to their prospective immunomodulatory impact.
钠-葡萄糖协同转运蛋白2抑制剂（SGLT2抑制剂）已从最初作为抗糖尿病药物的角色发展而来，因其显著的心脏保护和肾脏保护特性而获得认可。它们已成为充血性心力衰竭和蛋白尿性慢性肾脏病（CKD）治疗指南的关键组成部分。这些益处不仅限于血糖控制，因为心血管和肾脏结局的改善迅速出现。最近的研究揭示了SGLT2抑制剂的免疫调节特性；因此，阐明了它们影响免疫系统和炎症的潜力。这篇综述全面探讨了关于SGLT2抑制剂对免疫系统和炎症影响的当前知识状态，重点关注临床前和临床证据。该综述深入研究了它们的抗炎和免疫调节作用，提供了对临床意义的见解，并探索了与其潜在免疫调节影响相关的新兴研究领域。
